Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 9/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.51 |
| ▸ | TMPRSS4 | Q9NRS4 | 4/20 | 0.51 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.51 |
| ▸ | JUN | P05412 | 5/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.48 |
| ▸ | RELA | Q04206 | 5/20 | 0.48 |
| ▸ | IKBKB | O14920 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MYLK | Q15746 | 1/20 | 0.46 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.46 |
| ▸ | XPO1 | O14980 | 1/20 | 0.46 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241964 | 1.00 | P2RX1 (0.51) | P2RX1P2RX7TMPRSS4P2RX4TLR7 | |
| SCHEMBL26214027 | 0.88 | P2RX1 (0.53) | P2RX1P2RX7TMPRSS4P2RX4TLR7 | |
| SCHEMBL30554617 | 0.83 | KDR (0.54) | TMPRSS4MEN1KDRKMT2AMAPT | |
| SCHEMBL3246689 | 0.83 | KDR (0.54) | TMPRSS4MEN1KDRKMT2AMAPT | |
| SCHEMBL17413358 | 0.82 | NR1H4 (0.50) | TMPRSS4KDRMAPT | |
| SCHEMBL30554581 | 0.81 | TMPRSS4 (0.54) | TMPRSS4MEN1KDRKMT2AMAPT | |
| SCHEMBL3242642 | 0.81 | TMPRSS4 (0.54) | TMPRSS4MEN1KDRKMT2AMAPT | |
| SCHEMBL2788022 | 0.78 | NR1H4 (0.43) | P2RX1MEN1KMT2AMAPT | |
| SCHEMBL30554602 | 0.78 | AR (0.49) | — | |
| SCHEMBL3235641 | 0.78 | AR (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | claimed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | claimed |
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | disclosed |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | disclosed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | P2RX1 2486/4885P2RX7 2018/4885TMPRSS4 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.